Key facts
- This page summarizes Tina Marriott's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 1 reported transaction and 6 derivative rows are listed below.
- Accepted by SEC: 19 Nov 2024, 18:26.
Tina Marriott - 15 Nov 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Reporting relationship
- President and COO
- Issuer ticker
- RXRX
- Reported as of
- 15 Nov 2024
- Net transaction value
- -$88,216
- SEC form
- 4
- Accepted by SEC
- 19 Nov 2024, 18:26:17 UTC
- Prior SEC filing
- 28 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Jonathan Golightly, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Tina Marriott filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 19 Nov 2024.
Change
- Previous filing in this sequence was filed on 28 Oct 2024.
- Current net transaction value: -$88,216.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RXRX
transaction
Class A Common Stock
Tax liability
- Transaction value
- $88,216
- Shares
- -14,286
- Change %
- -2.7%
- Price
- $6.18
- Shares after
- 506,852
- Date
- 15 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 452,000
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $1.06
- Footnotes
- F2
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 434,122
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $8.55
- Footnotes
- F3
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 159,226
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
- Footnotes
- F4
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,784
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 150,000
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $2.48
- Footnotes
- F5
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 447,917
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $10.09
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
Footnote F2
Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
Footnote F3
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Footnote F4
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Footnote F5
One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
Footnote F6
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.